Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2020
August 2020, Vol 11, No 4 | Payers' Perspectives in Oncology: ASCO 2020 Highlights
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Managed Care, Oncology, and Telehealth in the Era of COVID-19
COVID-19
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
“COVID-19 has been like a 9/11 moment in healthcare,” said Michael Kolodziej, MD, Senior Advisor, ADVI Health, at the Association for Value-Based Cancer Care (AVBCC) July 28, 2020, webcast. “We don’t have a playbook. It’s required us to rethink.”
Read More
No Survival Benefit with Surgery and Radiation Added to Systemic Therapy in Patients with Newly Diagnosed Stage IV Breast Cancer
By
Phoebe Starr
Breast Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Early locoregional therapy with surgery and radiation does not improve overall survival (OS) in women with newly diagnosed stage IV breast cancer and an intact primary tumor compared with systemic therapy alone, according to the results of the randomized ECOG-ACRIN E2108 phase 3 clinical trial.
Read More
Pembrolizumab Added to First-Line Chemotherapy Improves Progression-Free Survival in Metastatic TNBC
By
Wayne Kuznar
Breast Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Pembrolizumab (Keytruda) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with chemotherapy alone as a first-line treatment for patients with metasstatic triple-negative breast cancer (TNBC) whose tumors express PD-L1.
Read More
CAR T-Cell Therapy Shows Deep, Durable Responses in Relapsed or Refractory Multiple Myeloma
By
Chase Doyle
Multiple Myeloma
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Cellular therapy is becoming an attractive option for heavily pretreated patients with relapsed or refractory multiple myeloma.
Read More
Pembrolizumab Doubles Progression-Free Survival in Subset of Patients with Metastatic Colorectal Cancer
By
Chase Doyle
Colon Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
There is a new standard of care in the first-line treatment setting for the subset of patients with advanced colorectal cancer (CRC) that is associated with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR), according to data presented at the ASCO 2020 virtual annual meeting.
Read More
Nivolumab plus Ipilimumab May Be a New First-Line Option for Patients with MSI-H or dMMR Metastatic Colorectal Cancer
By
Wayne Kuznar
Colon Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
The first-line immunotherapy combination of nivolumab (Opdivo) and low-dose ipilimumab (Yervoy) continues to show robust, durable clinical benefit, with a deepening of response, in patients with microsatellite instability high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer (CRC), according to results presented at the ASCO 2020 virtual annual meeting.
Read More
Maintenance Avelumab New Standard of Care for Advanced Bladder Cancer
By
Phoebe Starr
Bladder Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Interim analysis of the phase 3 JAVELIN Bladder 100 clinical trial showed that maintenance therapy with the PD-L1 inhibitor avelumab (Bavencio) plus best supportive care significantly prolonged overall survival (OS) versus best supportive care alone in patients with advanced urothelial carcinoma whose disease did not progress with first-line platinum-based chemotherapy.
Read More
Long-Term Data Support Use of Acalabrutinib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
By
Chase Doyle
Leukemia
,
Lymphoma
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Targeted therapy with the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib (Calquence), which is currently approved for the treatment of patients with non-Hodgkin lymphoma, has demonstrated durable remissions in treatment-naïve patients with chronic lymphocytic leukemia (CLL), according to the long-term data from the phase 2 CLL-001 study, which were presented at the ASCO 2020 virtual annual meeting.
Read More
How COVID-19 Is Affecting Patient Advocacy Groups: Financial Need Increasing
COVID-19
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Since March 2020, Cancer Support Community has broken records for the number of calls coming into its national network, said Elizabeth Franklin, LGSW, ACSW, Executive Director of the Cancer Policy Institute and Co-Chair of the Policy and Advocacy Committee of the Academy of Oncology Nurse & Patient Navigators (AONN+), in a webinar of the Association for Value-Based Cancer Care (AVBCC) on COVID-19.
Read More
CAR T-Cell Therapy Shows Highly Durable Remissions in CLL and B-Cell Lymphoma
By
Chase Doyle
Leukemia
,
Lymphoma
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
According to long-term follow-up data presented at the ASCO 2020 annual meeting, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has demonstrated ongoing durable remissions lasting up to 113 months for follicular lymphoma, 99 months for chronic lymphocytic leukemia (CLL), and 97 months for diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL).
Read More
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma